Profile data is unavailable for this security.
About the company
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
- Revenue in USD (TTM)0.00
- Net income in USD-44.80m
- Incorporated2004
- Employees10.00
- LocationAldeyra Therapeutics Inc131 HARTWELL AVENUE, SUITE 320LEXINGTON 02421United StatesUSA
- Phone+1 (781) 761-4904
- Fax+1 (302) 636-5454
- Websitehttps://www.aldeyra.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Atea Pharmaceuticals Inc | 0.00 | -174.01m | 266.90m | 75.00 | -- | 0.5821 | -- | -- | -2.07 | -2.07 | 0.00 | 5.43 | 0.00 | -- | -- | 0.00 | -31.67 | -5.90 | -32.99 | -6.98 | -- | -- | -- | -38.91 | -- | -- | 0.00 | -- | -- | -- | -17.30 | -- | -- | -- |
| Ocugen Inc | 9.33m | -49.67m | 267.58m | 65.00 | -- | 6.56 | -- | 28.69 | -0.1839 | -0.1839 | 0.0351 | 0.14 | 0.1365 | -- | -- | 143,492.30 | -72.71 | -83.56 | -90.53 | -97.79 | -- | -- | -532.51 | -2,921.94 | -- | -- | 0.0663 | -- | 142.60 | -- | 27.33 | -- | 39.08 | -- |
| Mersana Therapeutics Inc | 34.84m | -74.62m | 272.34m | 123.00 | -- | 260.02 | -- | 7.82 | -0.6129 | -0.6129 | 0.286 | 0.0085 | 0.1611 | -- | 69.67 | 283,227.70 | -34.51 | -61.68 | -50.38 | -81.35 | -- | -- | -214.19 | -622.19 | -- | -- | 0.9604 | -- | 38.65 | 28.32 | 15.94 | -- | 9.61 | -- |
| Aclaris Therapeutics Inc | 27.08m | -37.00m | 282.87m | 91.00 | -- | 2.17 | -- | 10.45 | -0.5198 | -0.5198 | 0.3806 | 1.82 | 0.1352 | -- | 78.61 | 297,582.40 | -18.47 | -47.29 | -20.87 | -53.87 | 53.53 | 44.00 | -136.65 | -549.18 | -- | -- | 0.00 | -- | 5.03 | 38.41 | -1.81 | -- | -0.703 | -- |
| Aldeyra Therapeutics Inc | 0.00 | -44.80m | 283.46m | 10.00 | -- | 3.33 | -- | -- | -0.7538 | -0.7538 | 0.00 | 1.43 | 0.00 | -- | -- | 0.00 | -33.86 | -36.79 | -39.67 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1522 | -- | -- | -- | 39.47 | -- | -- | -- |
| Vanda Pharmaceuticals Inc. | 190.86m | -16.39m | 285.71m | 203.00 | -- | 0.5279 | -- | 1.50 | -0.2824 | -0.2824 | 3.29 | 9.28 | 0.2967 | 9.30 | 5.30 | 940,187.20 | -2.55 | 6.61 | -2.95 | 7.62 | 93.62 | 90.55 | -8.59 | 15.18 | 4.84 | -- | 0.00 | 0.00 | -24.27 | -0.0496 | -60.02 | -36.96 | -56.77 | -- |
| C4 Therapeutics Inc | 33.67m | -105.50m | 285.89m | 145.00 | -- | 1.18 | -- | 8.49 | -1.70 | -1.70 | 0.5217 | 3.44 | 0.095 | -- | 6.21 | 232,193.10 | -29.76 | -25.91 | -33.20 | -29.45 | -- | -- | -313.35 | -292.35 | -- | -- | 0.00 | -- | -33.25 | 1.40 | -3.37 | -- | -8.68 | -- |
| iTeos Therapeutics Inc | 35.00m | -121.25m | 286.70m | 157.00 | -- | 0.4539 | -- | 8.19 | -3.15 | -3.15 | 0.9064 | 17.29 | 0.05 | -- | 1.43 | 222,929.90 | -17.31 | 5.84 | -18.16 | 7.02 | -- | -- | -346.44 | 22.09 | -- | -- | 0.00 | 0.00 | -95.29 | -- | -216.54 | -- | 68.45 | -- |
| Lyell Immunopharma Inc | 63.00k | -203.99m | 287.60m | 224.00 | -- | 0.498 | -- | 4,565.04 | -0.8013 | -0.8013 | 0.0003 | 2.07 | 0.00009 | -- | -- | 281.25 | -28.85 | -- | -30.32 | -- | -- | -- | -323,792.10 | -- | -- | -- | 0.00 | -- | -99.85 | -- | -28.13 | -- | -- | -- |
| Rezolute Inc | 0.00 | -69.31m | 290.29m | 59.00 | -- | 2.45 | -- | -- | -1.27 | -1.27 | 0.00 | 2.05 | 0.00 | -- | -- | 0.00 | -58.64 | -50.36 | -62.66 | -53.25 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -32.19 | -- | -- | -- |
| Lexicon Pharmaceuticals Inc | 5.23m | -216.39m | 291.87m | 285.00 | -- | 1.64 | -- | 55.82 | -0.7513 | -0.7513 | 0.018 | 0.4938 | 0.0175 | 0.6955 | 3.25 | 18,347.37 | -72.42 | -24.41 | -81.77 | -29.01 | 93.54 | 98.49 | -4,138.33 | -84.92 | 7.43 | -12.32 | 0.3588 | -- | 766.19 | -54.71 | -73.74 | -- | 37.68 | -- |
| Voyager Therapeutics Inc | 163.78m | 25.88m | 292.30m | 162.00 | 9.12 | 0.8851 | 9.45 | 1.78 | 0.5876 | 0.5876 | 2.94 | 6.06 | 0.4545 | -- | 14.29 | 1,011,012.00 | 7.18 | 0.6378 | 8.42 | 0.8203 | -- | -- | 15.80 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
| Nautilus Biotechnology Inc | 0.00 | -70.21m | 293.82m | 161.00 | -- | 1.31 | -- | -- | -0.561 | -0.561 | 0.00 | 1.78 | 0.00 | -- | -- | 0.00 | -24.29 | -- | -25.05 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -9.93 | -- | -- | -- |
Data as of Nov 21 2024. Currency figures normalised to Aldeyra Therapeutics Inc's reporting currency: US Dollar USD
46.75%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Perceptive Advisors LLCas of 30 Sep 2024 | 9.28m | 15.61% |
| Knoll Capital Management LPas of 30 Sep 2024 | 5.48m | 9.22% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 3.70m | 6.23% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 3.44m | 5.79% |
| Kennedy Capital Management LLCas of 30 Sep 2024 | 1.88m | 3.17% |
| Geode Capital Management LLCas of 30 Sep 2024 | 1.11m | 1.88% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 973.91k | 1.64% |
| Eagle Asset Management, Inc.as of 30 Sep 2024 | 709.52k | 1.19% |
| Invesco Capital Management LLCas of 30 Sep 2024 | 656.51k | 1.11% |
| Dimensional Fund Advisors LPas of 30 Sep 2024 | 551.12k | 0.93% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
